Ryusuke Hatae - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ryusuke Hatae

Showing results (61-70 of 66) with videos related to

Pageof 7

Sort By:

You have reached the last page of results.This site can display upto 66 results.

Scientific Reports|July 14, 2019

Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasmaMegumi Goto, Kenji Chamoto, Keiko Higuchi, et al.

Science Translational Medicine|December 14, 2022

Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancerKentaro Tanaka, Kenji Chamoto, Sho Saeki, et al.

The Journal of Clinical Investigation|April 1, 2024

Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockadeHidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, et al.

Nature|November 4, 2021

B cell-derived GABA elicits IL-10<sup>+</sup> macrophages to limit anti-tumour immunityBaihao Zhang, Alexis Vogelzang, Michio Miyajima, et al.

Acta Neuropathologica Communications|August 10, 2016

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomasHideyuki Arita, Kai Yamasaki, Yuko Matsushita, et al.

Acta Neuropathologica Communications|November 24, 2020

TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutationsHideyuki Arita, Yuko Matsushita, Ryunosuke Machida, et al.

Pageof 7

Search research articles

Showing results (61-70 of 66) with videos related to

Sort By:

Pageof 7

You have reached the last page of results.This site can display upto 66 results.

Scientific Reports|July 14, 2019

Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasmaMegumi Goto, Kenji Chamoto, Keiko Higuchi, et al.

Science Translational Medicine|December 14, 2022

Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancerKentaro Tanaka, Kenji Chamoto, Sho Saeki, et al.

The Journal of Clinical Investigation|April 1, 2024

Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockadeHidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, et al.

Nature|November 4, 2021

B cell-derived GABA elicits IL-10<sup>+</sup> macrophages to limit anti-tumour immunityBaihao Zhang, Alexis Vogelzang, Michio Miyajima, et al.

Acta Neuropathologica Communications|August 10, 2016

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomasHideyuki Arita, Kai Yamasaki, Yuko Matsushita, et al.

Acta Neuropathologica Communications|November 24, 2020

TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutationsHideyuki Arita, Yuko Matsushita, Ryunosuke Machida, et al.

Pageof 7